MAZE insider ownership: who sold, why, and what they still hold

What stands out

Catherine Sohn sold $1.1M of stock with no disclosed trading plan. The filings don't state a reason.Largest such sale, Jan 7, 2026

A share of stake is shown for 0 of the 6 officers and directors who sold. 18 are left out

Left out: Jason Coloma, Jonathan Lim, Sekar Kathiresan, Charles Homcy, Amy Bachrodt, Atul Dandekar, Harold Bernstein, Phillips Courtney, Nancy Andrews, Neil Exter, Richard Scheller, Catherine Sohn, Daniel Spiegelman, Misbah Tahir, Herve Hoppenot, Neil Kumar, Paula Johnson and Sophie Kornowski (share of stake is being verified).

Disclosed company stock is not an insider's whole wealth.

Who sold, and how much of their stake

Officers and directors, past 12 months. Their share of stake is being verified and is not shown yet; amounts and trading plans are below.

Harold Bernstein

President, R&D & CMO

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$9.5M97% planned, 3% to cover taxes

Jason Coloma

Chief Executive Officer, Director

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$6.2M90% planned, 10% to cover taxes

Atul Dandekar

Csbo

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$5.2M97% planned, 3% to cover taxes

Amy Bachrodt

SVP, Finance

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$1.6MDisclosed plan

Catherine Sohn

Director

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$1.1MNo plan disclosed

All 6 sellers

Selling by month

Officers and directors, Oct 2025 to Oct 2026. Each sale is counted once: under a disclosed plan, else to cover taxes, else no plan disclosed.

Disclosed planTo cover taxesNo plan disclosedOne dollar scale for every month; the tallest bar is labeled

Recent activity

Past 30 days, Sep 17, 2026 to Oct 16, 2026

Oct 1, 20262 executives sold 51K shares ($1.4M) under a disclosed trading plan. 16K shares came in from vesting or option exercises the same day, so their combined holdings fell by 35K net.

Who	Shares	Price	% of total stake	Total stake after	Trade date	Filed
Jason Coloma Chief Executive Officer, Director	34,501	$27.02	n/a	n/a	Oct 1, 2026	Oct 2, 2026
Harold Bernstein President, R&D & CMO	16,141	$26.93	n/a	n/a	Oct 1, 2026	Oct 2, 2026

Sep 29, 2026Atul Dandekar sold 7.5K shares ($203K) under a disclosed trading plan. 7.5K shares came in from vesting or option exercises the same day, so the holding rose by 0 net.

Who	Shares	Price	% of total stake	Total stake after	Trade date	Filed
Atul Dandekar Csbo	7,500	$27.06	n/a	n/a	Sep 29, 2026	Oct 1, 2026

"% of total stake" is the shares in an event against all the vested shares the person held that day, across every share class and holding entity, after that day's vesting. "n/a" means the person's holdings are not confirmed, or the row is a purchase. "Holdings record incomplete" means more shares were sold than the filings show the person held that day, so a percentage would be wrong.

Outside holders, reported separately

Third Rock Ventures IV, L.P. reported no open-market sales in the past 12 months. Large shareholders and the funds or companies that board members represent are not part of management, so they are left out of the figures above.

Details

Common questions

Is the Maze Therapeutics, Inc. CEO selling stock?

Yes. Jason Coloma sold 230K shares ($6.2M) in the past 12 months, 90% of it under a trading plan disclosed in the filings.

Why are Maze Therapeutics, Inc. insiders selling?

Filings rarely give a reason, and we don't guess at one. What they show is how the sales were made: 90% of sales by value ran under 10b5-1 trading plans disclosed in the filings, 5% were to cover taxes and 5% had no disclosed plan. A trading plan schedules sales in advance.

Are any Maze Therapeutics, Inc. insiders buying?

No. Officers and directors reported no purchases in the past 12 months.

The evidence

Who sold6 officers and directors: amount, % of holdings, trading plan

Who sold	Amount	% of holdings	Trading plan
Harold Bernstein President, R&D & CMO	$9.5M 263K shares	Not confirmed share of stake is being verified. Why	97% under a disclosed plan, 3% to cover taxes
Jason Coloma Chief Executive Officer, Director	$6.2M 230K shares	Not confirmed share of stake is being verified. Why	90% under a disclosed plan, 10% to cover taxes
Atul Dandekar Csbo	$5.2M 146K shares	Not confirmed share of stake is being verified. Why	97% under a disclosed plan, 3% to cover taxes
Amy Bachrodt SVP, Finance	$1.6M 38K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
Catherine Sohn Director	$1.1M 29K shares	Not confirmed share of stake is being verified. Why	No plan disclosed
Phillips Courtney GC and Corp. Secretary	$105K 4K shares	Not confirmed share of stake is being verified. Why	To cover taxes

Outside holder, reported separately: Third Rock Ventures IV, L.P. (a 10% owner, not part of management). No open-market sales reported in the period. Latest filing

The full ownership picture0 of 18 officers and directors confirmed

Vested shares across all share classes, held directly and through trusts, LLCs and family members, as reported on SEC Forms 3, 4 and 5. Unvested awards and options are never counted as owned shares.

Insider

Held Oct 16, 2025

Sold

Held Oct 16, 2026

Still held

Jason Coloma

Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Jason Coloma are complete.

Chief Executive Officer, Director

n/a

−230K

n/a

Vesting, gifts, unvested awards and holding lines for Jason Coloma

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Jason Coloma are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
679,390	$10.42	Feb 1, 2031	$11.3M
93,351	$10.42	Mar 16, 2032	$1.5M
80,904	$10.42	Mar 8, 2033	$1.3M
481,381	$10.42	Dec 8, 2034	$8.0M
51,861	$10.42	Mar 8, 2033	$861K
150,000	$45.61	Mar 1, 2036	$0

Estimate: options held × ($27.02 − strike price), using the most recent insider trade price on Form 4 (Oct 1, 2026), not a market close.

Jonathan Lim

Director

n/a

Vesting, gifts, unvested awards and holding lines for Jonathan Lim

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Jonathan Lim are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
5,704	$10.42	Mar 8, 2033	$95K
9,086	$10.42	Dec 8, 2034	$151K
18,000	$23.67	Sep 21, 2035	$60K
18,000	$23.58	Jun 7, 2036	$62K

Estimate: options held × ($27.02 − strike price), using the most recent insider trade price on Form 4 (Oct 1, 2026), not a market close.

Sekar Kathiresan

Director

n/a

Vesting, gifts, unvested awards and holding lines for Sekar Kathiresan

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Sekar Kathiresan are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
20,744	$10.42	May 18, 2032	$344K
9,086	$10.42	Dec 8, 2034	$151K
18,000	$23.67	Sep 21, 2035	$60K

Estimate: options held × ($27.02 − strike price), using the most recent insider trade price on Form 4 (Oct 1, 2026), not a market close.

Charles Homcy

Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. See the filing Sales and other transactions for Charles Homcy are complete.

Director

n/a

Vesting, gifts, unvested awards and holding lines for Charles Homcy

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Charles Homcy are complete; balances and unit counts will be added when the check is finished.

−36Kgifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
80,385	$10.42	Mar 3, 2031	$1.3M
5,704	$10.42	Mar 8, 2033	$95K
46,675	$10.42	Apr 22, 2034	$775K
45,638	$10.42	Dec 8, 2034	$758K
18,000	$23.67	Sep 21, 2035	$60K
18,000	$23.58	Jun 7, 2036	$62K

Estimate: options held × ($27.02 − strike price), using the most recent insider trade price on Form 4 (Oct 1, 2026), not a market close.

Amy Bachrodt

SVP, Finance

n/a

−38K

n/a

Vesting, gifts, unvested awards and holding lines for Amy Bachrodt

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Amy Bachrodt are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
1	$10.42	Feb 1, 2031	$17
486	$10.42	Mar 3, 2031	$8K
3,025	$10.42	Feb 17, 2032	$50K
2,377	$10.42	Oct 26, 2032	$39K
9,853	$10.42	Mar 3, 2033	$164K
23,834	$10.42	Apr 23, 2034	$396K
33,833	$10.42	Dec 8, 2034	$562K
32,000	$45.61	Mar 1, 2036	$0

Estimate: options held × ($27.02 − strike price), using the most recent insider trade price on Form 4 (Oct 1, 2026), not a market close.

Atul Dandekar

Csbo

n/a

−146K

n/a

Vesting, gifts, unvested awards and holding lines for Atul Dandekar

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Atul Dandekar are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
6,643	$10.42	Apr 11, 2031	$110K
20,204	$10.42	Mar 15, 2032	$335K
27,725	$10.42	Mar 3, 2033	$460K
25,930	$10.42	Apr 23, 2034	$430K
83,808	$10.42	Dec 8, 2034	$1.4M
38,000	$45.61	Mar 1, 2036	$0

Estimate: options held × ($27.02 − strike price), using the most recent insider trade price on Form 4 (Oct 1, 2026), not a market close.

Harold Bernstein

President, R&D & CMO

n/a

−263K

n/a

Vesting, gifts, unvested awards and holding lines for Harold Bernstein

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Harold Bernstein are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
144,521	$10.42	Oct 26, 2032	$2.4M
25,930	$10.42	Apr 23, 2034	$430K
142,101	$10.42	Dec 8, 2034	$2.4M
48,000	$45.61	Mar 1, 2036	$0

Estimate: options held × ($27.02 − strike price), using the most recent insider trade price on Form 4 (Oct 1, 2026), not a market close.

Phillips Courtney

GC and Corp. Secretary

n/a

−4K

n/a

Vesting, gifts, unvested awards and holding lines for Phillips Courtney

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Phillips Courtney are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
103,723	$10.42	Jul 17, 2034	$1.7M
35,680	$10.42	Dec 8, 2034	$592K
32,000	$45.61	Mar 1, 2036	$0

Estimate: options held × ($27.02 − strike price), using the most recent insider trade price on Form 4 (Oct 1, 2026), not a market close.

Nancy Andrews

Director

n/a

Vesting, gifts, unvested awards and holding lines for Nancy Andrews

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Nancy Andrews are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
20,744	$10.42	Feb 1, 2031	$344K
5,704	$10.42	Mar 8, 2033	$95K
9,086	$10.42	Dec 8, 2034	$151K
18,000	$23.67	Sep 21, 2035	$60K
18,000	$23.58	Jun 7, 2036	$62K

Estimate: options held × ($27.02 − strike price), using the most recent insider trade price on Form 4 (Oct 1, 2026), not a market close.

Neil Exter

Director

n/a

Vesting, gifts, unvested awards and holding lines for Neil Exter

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Neil Exter are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
16,000	$13.35	Aug 16, 2035	$219K
18,000	$23.67	Sep 21, 2035	$60K

Estimate: options held × ($27.02 − strike price), using the most recent insider trade price on Form 4 (Oct 1, 2026), not a market close.

Richard Scheller

Director

n/a

Vesting, gifts, unvested awards and holding lines for Richard Scheller

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Richard Scheller are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
8,109	$10.42	Jun 29, 2031	$135K
5,704	$10.42	Mar 8, 2033	$95K
9,086	$10.42	Dec 8, 2034	$151K
18,000	$23.67	Sep 21, 2035	$60K
18,000	$23.58	Jun 7, 2036	$62K

Estimate: options held × ($27.02 − strike price), using the most recent insider trade price on Form 4 (Oct 1, 2026), not a market close.

Catherine Sohn

Director

n/a

−29K

n/a

Vesting, gifts, unvested awards and holding lines for Catherine Sohn

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Catherine Sohn are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
316	$10.42	Mar 8, 2033	$5K
5,805	$10.42	Dec 8, 2034	$96K
18,000	$23.67	Sep 21, 2035	$60K

Estimate: options held × ($27.02 − strike price), using the most recent insider trade price on Form 4 (Oct 1, 2026), not a market close.

Daniel Spiegelman

Director

n/a

Vesting, gifts, unvested awards and holding lines for Daniel Spiegelman

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Daniel Spiegelman are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
20,744	$4.15	Oct 25, 2030	$474K
5,704	$10.42	Mar 8, 2033	$95K
9,086	$10.42	Dec 8, 2034	$151K
18,000	$23.67	Sep 21, 2035	$60K
18,000	$23.58	Jun 7, 2036	$62K

Estimate: options held × ($27.02 − strike price), using the most recent insider trade price on Form 4 (Oct 1, 2026), not a market close.

Misbah Tahir

Chief Financial Officer

n/a

Vesting, gifts, unvested awards and holding lines for Misbah Tahir

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Misbah Tahir are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
325,000	$15.32	Sep 1, 2035	$3.8M
40,000	$45.61	Mar 1, 2036	$0

Estimate: options held × ($27.02 − strike price), using the most recent insider trade price on Form 4 (Oct 1, 2026), not a market close.

Herve Hoppenot

Director

n/a

Vesting, gifts, unvested awards and holding lines for Herve Hoppenot

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Herve Hoppenot are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
36,000	$27.52	Oct 5, 2035	$0
18,000	$23.58	Jun 7, 2036	$62K

Estimate: options held × ($27.02 − strike price), using the most recent insider trade price on Form 4 (Oct 1, 2026), not a market close.

Neil Kumar

Director

n/a

Vesting, gifts, unvested awards and holding lines for Neil Kumar

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Neil Kumar are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
33,417	$30.38	Mar 26, 2036	$0

Estimate: options held × ($27.02 − strike price), using the most recent insider trade price on Form 4 (Oct 1, 2026), not a market close.

Paula Johnson

Director

n/a

Vesting, gifts, unvested awards and holding lines for Paula Johnson

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Paula Johnson are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
36,000	$27.66	Aug 12, 2036	$0

Estimate: options held × ($27.02 − strike price), using the most recent insider trade price on Form 4 (Oct 1, 2026), not a market close.

Sophie Kornowski

Director

n/a

Vesting, gifts, unvested awards and holding lines for Sophie Kornowski

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Sophie Kornowski are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
36,000	$27.66	Aug 12, 2036	$0

Estimate: options held × ($27.02 − strike price), using the most recent insider trade price on Form 4 (Oct 1, 2026), not a market close.

Holdings and share of stake for Maze Therapeutics, Inc. are being verified, so no balances, unit counts or percentages are shown. Sales, proceeds, plan and tax status, titles and dates come straight from individual filings.

What explains the selling$23.7M of sales by plan status, purpose, seller and month

Officer and director open-market sales: $23.7M across 709,871 shares. Plan status and stated purpose are separate questions, and a sale can have both.

By plan status

Disclosed plan · $21.4M · 90%

10%

The lighter segment is sales with no plan disclosed in the filing ($2.3M), including tax-related sales outside a plan.

No plan disclosed · $1.1M

Sales with no 10b5-1 plan and no tax reference in the filing. $1.1M of it is Catherine Sohn. No plan disclosed is a statement about the filing, not about why the sale happened. Largest such sale: Catherine Sohn, Jan 7, 2026

Taxes

$1.1M of sales (4.8%) cite tax obligations in their footnotes. Example: Phillips Courtney, Sep 3, 2026

Seller	Shares sold	Proceeds	Under a disclosed plan	Share of total	Sales dates
Harold Bernstein President, R&D & CMO	263K	$9.5M	97%	40%	Dec 29, 2025 to Oct 1, 2026
Jason Coloma Chief Executive Officer, Director	230K	$6.2M	90%	26%	May 15, 2026 to Oct 1, 2026
Atul Dandekar Csbo	146K	$5.2M	97%	22%	Dec 29, 2025 to Sep 29, 2026
Amy Bachrodt SVP, Finance	38K	$1.6M	100%	7%	Dec 29, 2025 to Apr 1, 2026
Catherine Sohn Director	29K	$1.1M	0%	5%	Jan 6, 2026 to Jan 7, 2026
Phillips Courtney GC and Corp. Secretary	4K	$105K	0%	0.4%	Sep 2, 2026 to Sep 3, 2026

Sales by month

Month	Sale proceeds	Disclosed plan	To cover taxes	No plan disclosed
Oct 2025	$0	$0	$0	$0
Nov 2025	$0	$0	$0	$0
Dec 2025	$5.4M	$5.4M	$0	$0
Jan 2026	$3.1M	$2.0M	$0	$1.1M
Feb 2026	$1.3M	$1.3M	$0	$0
Mar 2026	$2.7M	$2.7M	$0	$0
Apr 2026	$706K	$706K	$0	$0
May 2026	$1.5M	$1.5M	$0	$0
Jun 2026	$1.5M	$1.5M	$0	$0
Jul 2026	$1.7M	$1.7M	$0	$0
Aug 2026	$1.6M	$1.6M	$0	$0
Sep 2026	$2.9M	$1.8M	$1.1M	$0
Oct 2026	$1.4M	$1.4M	$0	$0

Known gaps and uncertainty18 officers and directors not confirmed

Holdings and share of stake are being verified. Balances, unit counts and every share-of-stake figure for Maze Therapeutics, Inc. are held back until that check is finished. Sales, proceeds, plan and tax status, titles and dates come straight from individual filings and are complete.

External context: we only cite outside events when a documented connection exists. None is shown for this period.

Sources and methodology106 filings on record, 66 filed in the 12-month period, and how we read them

All 106 Forms 3, 4 and 5 on record for Maze Therapeutics, Inc. (SEC CIK 1842295), filed from Jan 30, 2025 to Oct 2, 2026; 66 of them were filed in the 12 months this page covers, retrieved from SEC EDGAR on Oct 16, 2026. Prices are the ones reported in each filing, often weighted averages.

Holdings. Each holding line (a share class plus an owner, such as a trust or LLC) carries its last reported balance forward. Entities first reported during the period start at zero, so transfers between an insider's own trusts don't count as selling. Lines not reported for three years or more are listed separately and left out of totals.

Sales. A sale counts as under a 10b5-1 plan if its footnote cites one or the filing's Rule 10b5-1 box is checked, and as tax-related if its footnote cites tax obligations or sell-to-cover. Shares withheld by the company for taxes are listed separately. Sales with neither attribute are labeled "no plan disclosed".

Full methodology

Former or inactive filers (4)No filing in 18 months; last reported balances, not in any total

Name	Last filed	Last reported balance
James Brush	Jan 30, 2025	No balance on record
ARCH Venture Partners X, LLC	Jan 30, 2025	No balance on record
Alan Colowick		No balance on record
Jeffrey Tong		No balance on record

Spotted something wrong on this page? Report an error. We check every report against the SEC filing and list what we fix in the corrections log.

Maze Therapeutics, Inc. insiders sold $23.7M in the past 12 months. How much of their stake is that?

What stands out

Who sold, and how much of their stake

Selling by month

Recent activity

Outside holders, reported separately

Common questions

Is the Maze Therapeutics, Inc. CEO selling stock?

Why are Maze Therapeutics, Inc. insiders selling?

Are any Maze Therapeutics, Inc. insiders buying?

The evidence

No plan disclosed · $1.1M

Taxes

Sales by month